TD2 logo color - Copy

TD2 provides innovative services for improved and accelerated development of medicines for glioblastoma. Our team has deep experience and understanding in GBM PDX models for preclinical development. This combined with regulatory affairs expertise, guides customized clinical trial design and execution. Our capabilities encourage the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints.


Meet the Team


Marc Appelbaum

Vice President, Business Development


Paul Salvo

Director, Business Development